FINWIRES · TerminalLIVE
FINWIRES

月曜早朝の米ドルはまちまちの動き、今週は小売売上高とS&Pグローバル速報値に注目

By

-- 月曜早朝、米ドルは主要貿易相手国に対してまちまちの動きを見せた。ポンドと円に対しては上昇、ユーロとカナダドルに対しては下落した。火曜日の小売売上高データと木曜日のS&Pグローバル速報値に注目が集まる中、市場は動きを見せている。 連邦準備制度理事会(FRB)当局者は、4月28~29日に開催される連邦公開市場委員会(FOMC)会合を前に、静穏期に入っている。 月曜日は経済指標の発表はない。 火曜日は、3月の小売売上高に加え、フィラデルフィア連銀による4月の非製造業景況指数、レッドブック週間既存店売上高、3月の住宅販売保留件数、2月の企業在庫データ、そしてケビン・ウォーシュ氏のFRB議長指名承認公聴会が予定されている。 水曜日は、2月の州別雇用統計、週間住宅ローン申請件数、石油在庫データが注目される。 木曜日は多忙な日程で、週間新規失業保険申請件数、S&Pグローバルによる4月の製造業・サービス業景況指数速報値、週間天然ガス在庫データが注目される。 ミシガン大学による4月の消費者信頼感指数の最終値と、カンザスシティ連銀による4月のサービス業景況指数は、東部時間午前11時に発表される予定です。 月曜日を前にした為替相場の動向を簡単にまとめると以下のようになります。 ユーロ/米ドルは、金曜日の米国市場終値1.1770から1.1772へと小幅上昇しましたが、金曜午前の同時刻には1.1797を下回っていました。昨夜発表されたデータによると、ユーロ圏の建設生産高は2月にさらに減少しました。欧州中央銀行(ECB)のクリスティーヌ・ラガルド総裁は、東部時間午後12時40分に講演を行う予定です。次回のECB会合は4月30日に予定されています。 英ポンド/米ドルは、金曜日の米国市場終値1.3522から1.3519へと下落し、金曜午前の同時刻には1.3528でした。月曜日には英国の経済指標の発表予定はありません。イングランド銀行の次回会合は4月30日に予定されています。 米ドル/円は、金曜日の米国市場終値158.5612円から158.8761円まで上昇しましたが、金曜午前の同時刻には159.1673円を下回っていました。昨夜発表されたデータによると、日本の企業サービス購入は2月も引き続き縮小しましたが、縮小幅は前月より縮小幅が縮小しました。日本銀行の次回会合は4月27~28日に予定されています。 米ドル/カナダドルは、金曜日の米国市場終値1.3685円から1.3683円まで下落しましたが、金曜午前の同時刻には1.3677円を上回っていました。カナダの3月消費者物価指数は午前8時30分(東部時間)に発表され、続いて午前10時30分(東部時間)にカナダ銀行による第1四半期企業景況感調査が発表される予定です。カナダ銀行の次回会合は4月29日に予定されています。

Related Articles

Equities

Canada's Retail Sales Momentum May Fade Later in The Year, Says National Bank

Statistics Canada's advance estimate points to a 0.6% month-over-month nominal increase in March retail sales, said National Bank of Canada after Friday's data.Given the surge in gasoline prices that occurred in the month, this figure heavily reflects higher prices at the pump. As a result, in real terms, retail sales could register a contraction in the final month of Q1, noted the bank.Nonetheless, for the quarter, information received to date indicates that real retail sales could grow at a 4.7% annualized pace, following a 2.0% decline in the previous quarter -- marking the strongest quarterly performance since Q4 2024, stated National Bank.This is all the more impressive as it is occurring against a backdrop of demographic contraction, pointed out the bank.Indeed, the most recent figures from StatsCan indicate that the country's population declined for a second consecutive quarter -- an unprecedented development.As a result, real retail spending per capita is tracking a 5.2% increase in Q1, a rebound from the sluggish prints seen in 2025. Still, National Bank thinks that this momentum could fade fast as the year progresses.As a result of the conflict in the Middle East, households will face an erosion in purchasing power in the coming months. This, combined with a mortgage interest-payment shock and a still fragile labor market, could weigh on discretionary spending going forward, according to the bank.

$$CXY
Australia

Cinemark Likely to Benefit From Release Slate, Wedbush Says

Cinemark (CNK) is set to benefit from a more consistent release slate over the next several quarters and further market share gains, Wedbush said in a Monday note."The summer slate, especially in Q3, is shaping up very nicely," the report said.The note said theater investments, including laser projectors, premium seats and screens, IMAX expansion, and strategic pricing could drive market share gains. It also pointed to other benefits such as new builds and returning cash to shareholders.For its Q1 results due May 1, Wedbush expects Cinemark to post Q1 revenue of $638 million, against consensus of $629 million, and a loss of $0.03 per share, against consensus of $0.16 loss.Wedbush kept its outperform rating and a $37 price target.Price: $29.40, Change: $+0.92, Percent Change: +3.23%

$CNK
Asia Markets

Swiss Market Index Closes Little Changed; Santhera Shares Jump

The blue-chip Swiss Market Index was down 0.03% on Monday's close, as investors gear up for a busy week of corporate updates, economic data prints and key monetary policy decisions.Santhera Pharmaceuticals (SANN.SW) secured a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use to expand the approval of its Duchenne muscular dystrophy drug Agamree to include the treatment of children who are at least two years old. The drug is currently approved for use on patients aged four and above. The Swiss specialty pharmaceutical company's shares gained 8.38% at closing.Meanwhile, RBC Capital Markets reiterated its outperform rating on Lonza Group (LONN.SW), with a price target of 670 francs, amid expectations that the Swiss pharmaceutical manufacturer's upcoming first-quarter update would be "uneventful." At the end of the trading day, the stock was up 1.83%."We do not see the Q1 qualitative update on 8 May to be a major catalyst for the stock now that Vacaville-specific commentary will no longer be provided, and any further weakness in Specialized Modalities should not be a surprise. We have also taken the opportunity to refresh and add to our commercial product (Enflonsia) and pipeline trackers. There has been some clinical progress, but consensus forecasts have been pushed out a little (aggregate peak sales estimates are unchanged)," the research firm said, noting that it views Lonza as an "attractive and undervalued compounding investment story."The local economic news calendar was empty for the day, while the release of the Swiss KOF Economic Barometer and the UBS & CFA Society Switzerland's economic sentiment index for April, as well as the country's March retail sales figures are on the agenda over the coming days. Market watchers are also awaiting the rate decisions of the US Federal Reserve, the European Central Bank, and the Bank of England.

$^SSMI$LONN.SW$SANN.SW